Pivotal bioVenture Partners Investment Advisor’s Bolt Biotherapeutics BOLT Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio BOLT Stock Details BOLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-42,581	Closed	-$172K	–	14
2026 Q1	$172K	Sell	42,581 -51,992	-55%	-$271K	0.06%	13
2025 Q4	$517K	Hold	94,573	–	–	0.2%	12
2025 Q3	$503K	Hold	94,573	–	–	0.29%	10
2025 Q2	$546K	Hold	94,573	–	–	0.34%	12
2025 Q1	$757K	Hold	94,573	–	–	0.61%	11
2024 Q4	$1.02M	Hold	94,573	–	–	0.69%	9
2024 Q3	$1.23M	Hold	94,573	–	–	0.73%	10
2024 Q2	$1.42M	Hold	94,573	–	–	1.09%	8
2024 Q1	$2.65M	Hold	94,573	–	–	1.7%	8
2023 Q4	$2.12M	Hold	94,573	–	–	0.54%	10
2023 Q3	$1.97M	Hold	94,573	–	–	0.78%	11
2023 Q2	$2.42M	Hold	94,573	–	–	0.8%	10
2023 Q1	$2.63M	Hold	94,573	–	–	1.08%	10
2022 Q4	$2.46M	Hold	94,573	–	–	1.07%	9
2022 Q3	$2.8M	Hold	94,573	–	–	1.02%	10
2022 Q2	$3.86M	Hold	94,573	–	–	1.94%	9
2022 Q1	$5.18M	Hold	94,573	–	–	2.45%	9
2021 Q4	$9.27M	Hold	94,573	–	–	3.88%	9
2021 Q3	$23.9M	Hold	94,573	–	–	8.46%	4
2021 Q2	$29.2M	Hold	94,573	–	–	11.53%	3
2021 Q1	$62.2M	Buy	+94,573	New	+$61.5M	19.97%	2

Other funds holding BOLT

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

T3 Companies New York $93.7M AUM

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's BOLT Position: Q2 2026 in Review

Pivotal bioVenture Partners Investment Advisor sold out of Bolt Biotherapeutics (BOLT) in Q2 2026, closing a stake of 42,581 shares — an estimated $172K sold.

Pivotal bioVenture Partners Investment Advisor first reported a position in BOLT in Q1 2021 and held it in 21 quarters. The position peaked at $62.2M in Q1 2021. 23 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.

Pivotal bioVenture Partners Investment Advisor reported no remaining Bolt Biotherapeutics position as of Q2 2026 after selling out during the quarter.
Pivotal bioVenture Partners Investment Advisor sold 42,581 Bolt Biotherapeutics shares in Q2 2026, an estimated $172K.
Pivotal bioVenture Partners Investment Advisor first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 21 quarters.
Pivotal bioVenture Partners Investment Advisor's Bolt Biotherapeutics position peaked at $62.2M in Q1 2021.
23 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q2 2026, filed 13 Aug 2026.